ArticleProbiotics and antimicrobial proteins2026
Non-targeted Metabolomic and Intestinal Microbiota Analysis of Ligilactobacillus salivarius X9 in Enterotoxigenic Escherichia coli K88-induced Enteritis in Mice.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Study on Biological Characteristics and Functions of Three Porcine-Derived Lactic Acid Bacteria.Animals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Enterotoxigenic Escherichia coli K88 (ETEC K88), a member of the E. coli family, poses a serious threat to human health and animal husbandry due to its high morbidity and mortality rates. Herein, three strains of lactic acid bacteria were isolated from the feces of Luhua chickens raised on farms in the Inner Mongolia Autonomous Region, China. Their antibacterial spectrum, acid resistance, bile salt resistance, antibiotic sensitivity, and other biological characteristics were evaluated. The results showed that Ligilactobacillus salivarius X9 (L. salivarius X9) exhibited superior acid and bile salt tolerance, favorable safety properties, and the strongest antibacterial activity against multidrug-resistance ETEC K88. Therefore, this study evaluated whether L. salivarius X9 could mitigate intestinal inflammatory damage induced by ETEC K88 in mice. The results showed that IL-1β levels were significantly reduced in the L. salivarius X9 treatment group compared with the intragastric ETEC K88 model group (GI group), while IL-10 levels were significantly upregulated in the treatment group. In addition, preconditioning with L. salivarius X9 increased the relative abundance of gut probiotics, regulated the accumulation of L-arginine and stearic acid, alleviated morphological damage in the mouse ileum induced by ETEC K88, and prevented intestinal inflammation. Our findings provide a foundation for the clinical application of L. salivarius X9 in the prevention of intestinal inflammation caused by ETEC K88.
Indexed as
Identifiers
41258380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.